全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Molecular Docking and Pharmacological Property Analysis of Phytochemicals from Clitoria ternatea as Potent Inhibitors of Cell Cycle Checkpoint Proteins in the Cyclin/CDK Pathway in Cancer Cells

DOI: 10.4236/cmb.2019.93007, PP. 81-94

Keywords: Anticancer, ADME/T, Clitoria ternatea, Docking, Kaempferol, Quercetin

Full-Text   Cite this paper   Add to My Lib

Abstract:

Cancer comprises a group of diseases which are involved in the aberrant growth of the cells causing disruption of normal body function. Due to the lack of proper sophisticated treatments this nasty disease leads to the death of most of the patients affected with it. Moreover, treatments like chemotherapy involve other post-treatment complications which make them unfavorable for extended use. Medicinal plants possess many phytochemicals of great therapeutic value and many of them are effective in killing cancer cells. These compounds working by variety of mechanisms and in most of the cases exhibit their anticancer potentiality by inhibiting many proteins involved in cell growth and division. Molecular docking is a computational approach which facilitates the finding of the best molecule from a group which may bind with the highest affinity with the intended target by providing a virtual biological system. This process works on the basis of specific algorithm and involves scoring function to rank the molecules that fit with the target. This study has been designed to investigate the potentiality of four phytochemicals from Clitoria ternateaKaempferol, Myricetin, P-Hydroxycinnamic acid and Quercetin as inhibitors of two cell cycle checkpoint proteins—Cyclin Dependent Kinase-2 (CDK-2) and Cyclin Dependent Kinase-6 (CDK-6) in Cyclin/CDK pathway. Quercetin and Myricetin docked with higher affinity with CDK-2 and CDK-6 respectively. Drug likeness property analysis and ADME/T test impose computational approach to investigate physicochemical and pharmacological properties of candidate drug molecules. P-Hydroxycinnamic acid performed well in both drug likeness property analysis and ADME/T than Quercetin and Myricetin. So, P-Hydroxycinnamic acid is the best finding of this experiment.

References

[1]  Burrell, R.A., McGranahan, N., Bartek, J. and Swanton, C. (2013) The Causes and Consequences of Genetic Heterogeneity in Cancer Evolution. Nature, 501, 338-345.
https://doi.org/10.1038/nature12625
[2]  Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70.
https://doi.org/10.1016/S0092-8674(00)81683-9
[3]  Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108.
https://doi.org/10.3322/caac.21262
[4]  Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.
[5]  Desai, A.G., et al. (2008) Medicinal Plants and Cancer Chemoprevention. Current Drug Metabolism, 9, 581-591.
https://doi.org/10.2174/138920008785821657
[6]  Jacob, L. and Latha, M.S. (2012) Anticancer Activity of Clitoria ternatea Linn. against Dalton’s Lymphoma. International Journal of Pharmacognosy and Phytochemical Research, 4, 207-212.
https://ijppr.com
[7]  Al-Snafi, A.E. (2016) Pharmacological Importance of Clitoria ternatea–A Review. IOSR Journal of Pharmacy, 6, 68-83.
http://iosrjournals.org/IOSR-PHR.html
[8]  Lijon, M.B., Meghla, N.S., Jahedi, E., Rahman, M.A. and Hossain, I. (2017) Phytochemistry and Pharmacological Activities of Clitoria ternatea. International Journal of Natural and Social Sciences, 4, 1-10.
https://ijnss.org/
[9]  Nevins, J.R., Leone, G., DeGregori, J. and Jakoi, L. (1997) Role of the Rb/E2F Pathway in Cell Growth Control. Journal of Cellular Physiology, 173, 233-236.
https://doi.org/10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F
[10]  Sherr, C.J. and Roberts, J.M. (1999) CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression. Genes & Development, 13, 1501-1512.
https://doi.org/10.1101/gad.13.12.1501
[11]  Ho, A. and Dowdy, S.F. (2002) Regulation of G1 Cell-Cycle Progression by Oncogenes and Tumor Suppressor Genes. Current Opinion in Genetics & Development, 12, 47-52.
https://doi.org/10.1016/S0959-437X(01)00263-5
[12]  Boonstra, J. (2003) Progression through the G1-Phase of the on-Going Cell Cycle. Journal of Cellular Biochemistry, 90, 244-252.
https://doi.org/10.1002/jcb.10617
[13]  Harper, J.W. and Elledge, S.J. (1996) Cdk Inhibitors in Development and Cancer. Current Opinion in Genetics & Development, 6, 156-164.
https://doi.org/10.1016/S0959-437X(96)90011-8
[14]  Hall, M. and Peters, G. (1996) Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer. Advances in Cancer Research, 68, 67-108.
https://doi.org/10.1016/S0065-230X(08)60352-8
[15]  Cicenas, J. and Valius, M. (2011) The CDK Inhibitors in Cancer Research and Therapy. Journal of Cancer Research and Clinical Oncology, 137, 1409.
https://doi.org/10.1007/s00432-011-1039-4
[16]  Zoete, V., Grosdidier, A. and Michielin, O. (2009) Docking, Virtual High Throughput Screening and in Silico Fragment-Based Drug Design. Journal of Cellular and Molecular Medicine, 13, 238-248.
https://doi.org/10.1111/j.1582-4934.2008.00665.x
[17]  Schneidman-Duhovny, D., Nussinov, R. and Wolfson, H.J. (2004) Predicting Molecular Interactions in Silico: II. Protein-Protein and Protein-Drug Docking. Current Medicinal Chemistry, 11, 91-107.
https://doi.org/10.2174/0929867043456223
[18]  Phillips, M.A., Stewart, M.A., Woodling, D.L. and Xie, Z.R. (2018) Has Molecular Docking Ever Brought Us a Medicine? In: Molecular Docking, IntechOpen, London.
[19]  Cheng, F., Li, W., Liu, G. and Tang, Y. (2013) In Silico ADMET Prediction: Recent Advances, Current Challenges and Future Trends. Current Topics in Medicinal Chemistry, 13, 1273-1289.
https://doi.org/10.2174/15680266113139990033
[20]  Moroy, G., Martiny, V.Y., Vayer, P., Villoutreix, B.O. and Miteva, M.A. (2012) Toward in Silico Structure-Based ADMET Prediction in Drug Discovery. Drug Discovery Today, 17, 44-55.
https://doi.org/10.1016/j.drudis.2011.10.023
[21]  Release, S. (2018) 2: Maestro, version 11.8. Schrödinger, LLC, New York.
https://www.schrodinger.com/maestro
[22]  Visualizer, D.S. (2012) Release 3.5. Accelrys Inc., San Diego, CA.
https://www.3dsbiovia.com
[23]  Spessard, G.O. (1998) ACD Labs/LogP dB 3.5 and ChemSketch 3.5. Journal of Chemical Information and Computer Sciences, 38, 1250-1253.
https://doi.org/10.1021/ci980264t
[24]  Lipinski, C.A. (2004) Lead-and Drug-Like Compounds: The Rule-of-Five Revolution. Drug Discovery Today: Technologies, 1, 337-341.
https://doi.org/10.1016/j.ddtec.2004.11.007
[25]  Yuriev, E. and Ramsland, P.A. (2013) Latest Developments in Molecular Docking: 2010-2011 in Review. Journal of Molecular Recognition, 26, 215-239.
https://doi.org/10.1002/jmr.2266
[26]  Hubbard, R.E. and Kamran Haider, M. (2001) Hydrogen Bonds in Proteins: Role and Strength. e LS.
https://doi.org/10.1038/npg.els.0003011
[27]  Sander, T. (2001) OSIRIS Property Explorer. Organic Chemistry Portal.
https://www.organic-chemistry.org/prog/peo/
[28]  Pollastri, M.P. (2010) Overview on the Rule of Five. Current Protocols in Pharmacology, 49, 9-12.
https://doi.org/10.1002/0471141755.ph0912s49
[29]  Li, A.P. (2001) Screening for Human ADME/Tox Drug Properties in Drug Discovery. Drug Discovery Today, 6, 357-366.
https://doi.org/10.1016/S1359-6446(01)01712-3
[30]  Guengerich, F.P. (1999) Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism. Annual Review of Pharmacology and Toxicology, 39, 1-17.
https://doi.org/10.1146/annurev.pharmtox.39.1.1

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133